Clinical Trials on Lymphoid Neoplasm

Total 106526 results

Thomas Jefferson University

Completed

Development of the Oncology Opportunity Cost Assessment Tool

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
University of California, San Francisco
Akili Interactive Labs, Inc.

Completed

Study of Attention and Memory Treatments for Cancer Survivors

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Adult Solid Neoplasm

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Shire

Active, not recruiting

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States, Canada, Puerto Rico
Jazz Pharmaceuticals

Completed

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States, Canada
Mayo Clinic

Recruiting

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Communication Issues in Patient and Provider Discussions of Immunotherapy

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

RefleXion PET/CT Imaging Performance in Patients With Various Malignancies

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Recruiting

Predicting the Impact of Treatment Toxicities on Health During Cancer (PATTERN)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm

United States
Mayo Clinic

Recruiting

Role of Gut Microbiome in Cancer Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations for the Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Withdrawn

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Thomas Jefferson University

Completed

Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Completed

Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Goethe University

Active, not recruiting

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

Germany
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

Lymphoblastic Lymphoma

China
Gilead Sciences

Terminated

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Follicular Lymphoma | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
Emory University

Completed

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT)

Lymphoblastic Lymphoma | Lymphoblastic Leukemia

United States
Jazz Pharmaceuticals

Approved for marketing

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma
Sherif S. Farag
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Leukemia, Myelogenous, Chronic | Hematopoetic Myelodysplasia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Acute Lymphoid Leukemia

Italy
Asan Medical Center

Terminated

Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) (AHCTALL)

Acute Lymphoid Leukemia

Korea, Republic of
Kite, A Gilead Company

Available

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma

United States
Acibadem University
The Scientific and Technological Research Council of Turkey; Acıbadem Labcell; Acıbadem Atunizade Hospital

Unknown

Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (ISIKOK-19)

Acute Lymphoblastic Leukemia | Non Hodgkin Lymphoma

Turkey
Jazz Pharmaceuticals

Terminated

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
Children's Mercy Hospital Kansas City
Millennium Pharmaceuticals, Inc.

Terminated

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
University Hospital, Lille
Assistance Publique - Hôpitaux de Paris; Hospices Civils de Lyon; Central Hospital... and other collaborators

Completed

Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia (Vandevol)

Acute Lymphoid Leukemia Relapse | Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant

France
Kjeld Schmiegelow
Danish Child Cancer Foundation; Nordic Society for Pediatric Hematology and...

Completed

Thiopurine EnhAnced Maintenance Therapy (TEAM)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

Denmark
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

United States, Canada

Clinical Trials on Lymphoid Neoplasm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations